136 related articles for article (PubMed ID: 35575415)
1. An aggressive lactotroph pituitary tumor in a young male: A pituitary carcinoma without metastasis.
Roelandt-Schumann FE; Vergeer RA; Korsten-Meijer AGW; Kramer MCA; Westerlaan HE; Pott JWR; Nuver J; van den Berg G; den Dunnen WFA
Clin Neuropathol; 2022; 41(5):211-218. PubMed ID: 35575415
[TBL] [Abstract][Full Text] [Related]
2. What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?
Phillips J; East HE; French SE; Melcescu E; Hamilton RD; Nicholas WC; Fratkin JF; Parent AD; Luzardo G; Koch CA
Hormones (Athens); 2012; 11(4):477-82. PubMed ID: 23422771
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine overcomes cabergoline resistance in a patient with Lactotroph Pituitary neuroendocrine tumor: a case report.
Lin S; Han C; Lou X; Wu ZB
Front Endocrinol (Lausanne); 2022; 13():955100. PubMed ID: 35983516
[TBL] [Abstract][Full Text] [Related]
4. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
6. Aggressive Pituitary Adenoma Not Fulfilling the New High-Risk Criteria with Progression after 18-Year Stable Clinical Course: Case Report.
Kawaguchi T; Ogawa Y; Watanabe M; Tominaga T
J Neurol Surg A Cent Eur Neurosurg; 2022 Jul; 83(4):391-395. PubMed ID: 33618408
[TBL] [Abstract][Full Text] [Related]
7. Aggressive giant prolactinoma: a case report.
Borhan MK; Tan FHS
J Med Case Rep; 2022 Apr; 16(1):170. PubMed ID: 35488355
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours.
Trouillas J; Delgrange E; Wierinckx A; Vasiljevic A; Jouanneau E; Burman P; Raverot G
Neuroendocrinology; 2019; 109(1):70-76. PubMed ID: 30943495
[TBL] [Abstract][Full Text] [Related]
9. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
10. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Ceccato F; Lombardi G; Albiger N; Mazzai L; Pambuku A; Rolma G; Zagonel V; Scaroni C
Anticancer Drugs; 2019 Jun; 30(5):533-536. PubMed ID: 30986806
[TBL] [Abstract][Full Text] [Related]
12. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
13. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
14. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
[TBL] [Abstract][Full Text] [Related]
15. Sellar neuroblastoma mimicking a pituitary tumour: case report and review of the literature.
Schmalisch K; Psaras T; Beschorner R; Honegger J
Clin Neurol Neurosurg; 2009 Nov; 111(9):774-8. PubMed ID: 19640636
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast Growth Factor Receptor-4 Expression in Pituitary Adenomas is Associated with Aggressive Tumor Features.
Durcan E; Keskin FE; Ozkaya HM; Sirolu S; Sahin S; Korkmaz OP; Gazioglu N; Tanriover N; Comunoglu N; Oz B; Kizilkilic O; Kadioglu P
Exp Clin Endocrinol Diabetes; 2022 Feb; 130(2):125-133. PubMed ID: 34255320
[TBL] [Abstract][Full Text] [Related]
17. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
18. Aggressive pituitary adenomas--diagnosis and emerging treatments.
Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
[TBL] [Abstract][Full Text] [Related]
19. Treatment Options for Gonadotroph Tumors: Current State and Perspectives.
Ilie MD; Raverot G
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32735647
[TBL] [Abstract][Full Text] [Related]
20. Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O; Lopes MB
Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
